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Syntenin-ALIX exosome biogenesis and budding
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Exosomes are small vesicles that are secreted by cells and act as mediators of cell to cell
communication. Because of their potential therapeutic signiﬁcance, important efforts are
being made towards characterizing exosomal contents. However, little is known about the
mechanisms that govern exosome biogenesis. We have recently shown that the exosomal
protein syntenin supports exosome production. Here we identify the small GTPase ADP
ribosylation factor 6 (ARF6) and its effector phospholipase D2 (PLD2) as regulators of
syntenin exosomes. ARF6 and PLD2 affect exosomes by controlling the budding of intra-
luminal vesicles (ILVs) into multivesicular bodies (MVBs). ARF6 also controls epidermal
growth factor receptor degradation, suggesting a role in degradative MVBs. Yet ARF6 does
not affect HIV-1 budding, excluding general effects on Endosomal Sorting Complexes
Required for Transport. Our study highlights a novel pathway controlling ILV budding and
exosome biogenesis and identiﬁes an unexpected role for ARF6 in late endosomal trafﬁcking.
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A
fter internalization, cell surface molecules can follow
different trafﬁcking routes. For example, from early
endosomes they can be sorted for recycling to the plasma
membrane or degradation in lysosomes. The formation and the
maturation of endosomes are essential in regulating this trafﬁc.
During maturation, inward invagination of the limiting mem-
brane of the endosome gives rise to intraluminal vesicles (ILVs).
The late endosome is then called a multivesicular body or MVB1.
This vesiculation has been shown to increase upon signalling via
growth factor receptors, and the inclusion in ILVs inactivates
signalling receptors because it deprives them from contact with
the cytosol2. MVBs move towards the perinuclear area of
the cell where they can directly fuse with lysosomes creating
hybrid organelles, where endocytosed cargos are degraded3.
Alternatively, MVBs can fuse with the plasma membrane
inducing the secretion in the extracellular environment of ILVs
that will be now called exosomes. Exosomes are proposed to
function as mediators of intercellular communication and might
lead to reprogramming of recipient cells4,5.
Multiple pathways seem to operate on endosomal membranes
and give rise to different populations of MVBs. Different
populations of ILVs, enriched in different lipids, can coexist6
and form within single MVBs that can be distinguished on the
basis of size and mechanism of formation7. The mechanisms of
ILV formation and sorting of endosomal proteins into these
vesicles are partially understood. The best described machinery
that drives ILV formation into MVB is the endosomal sorting
complexes required for transport (ESCRT) machinery. In this
pathway, ILV formation requires ubiquitination and the
sequential action of different components of the ESCRT8–10.
Yet ubiquitin and ESCRT-independent pathways have also been
identiﬁed and might coexist with ESCRT-dependent machinery
attesting for different MVB subpopulations fated for either
lysosomal degradation or exosomal release11–13. A population of
exosomes requires neutral sphingomyelinase 2 to produce
ceramide, thereby forming raft-based microdomains14. Higher-
order oligomerization of membrane complexes might also drive
exosome formation15. We have recently shown that the PDZ
protein syntenin stimulates exosome production and is required
for the budding of CD63-positive ILVs into MVBs16. Syntenin is
highly enriched in exosomes (ExoCarta exosome database
www.exocarta.org), and the stimulation of exosome production
by syntenin depends on the interaction of its N-terminal domain
with ALIX16, an auxiliary component of the ESCRT machinery
that supports viral budding17,18. Syntenin interaction with ALIX
mimics retroviral late domain protein–ALIX interaction16, which
is known to be essential for efﬁcient retroviral budding18. The
production of syntenin exosomes requires certain ESCRTs
components (that is, VPS22 and CHMP2A) but is independent
of others (CHMP3 and CHMP6)16. This suggests that the
biogenesis of exosomes might use alternative ESCRT pathways.
Importantly, syntenin PDZ domains directly bind to multiple
membrane receptors such as syndecans19 and the tetraspanin
CD63 (ref. 20), supporting their exosomal sorting16. We have
previously found that syntenin interacts genetically with the small
GTPase ADP-Ribosylation Factor 6 (ARF6), and that syntenin-
ARF6 interaction is crucial for early polarized movements during
zebraﬁsh development21. ARF6 is localized at the plasma
membrane and on endosomes, and regulates membrane trans-
port, vesicular trafﬁcking (endocytosis, recycling and exocytosis)
and membrane remodelling by regulating actin cytoskeleton and
phosphoinositides metabolism22,23. Like other small GTPases,
ARF6 works as a molecular switch that cycles between the active
(GTP-bound) and inactive (GDP-bound) state, and ARF6
function is under tight spatial control, which is mediated by
guanine nucleotide exchange factors (GEFs) that catalyse GTP
exchange23. Activated ARF6 has been shown to function through
activation of two major effectors, Phosphatidylinositol
4-Phosphate 5-Kinase (PIP5K) and Phospholipase D (PLD)24,25.
We have shown that ARF6 and its effector PIP5K control the
endocytic recycling of syntenin PDZ-interactors, that is,
syndecans, in a phosphatidylinositol 4,5-bisphosphate-dependent
manner and that this pathway is important for cell spreading26.
Here, testing for the impact of ARF6 on syntenin exosomes, we
identify ARF6 as a regulator of ILV budding and exosome
production. We show that these effects rely on the ARF6 effector
PLD2. These ﬁndings depict a role for ARF6 in late endosomal
events and contribute to our understanding of the mechanisms of
exosome biogenesis at the level of ILV budding.
Results
ARF6 regulates exosomes. Because of the genetic interaction
between ARF6 and syntenin and because ARF6-syntenin is
involved in endosomal trafﬁcking, we investigated the role of
ARF6 on the production of syntenin exosomes. We used MCF-7
cells as a model, in which ‘syntenin-exosomes’ represent up to
50% of the secreted particles16. Moreover, MCF-7 cell secreted
particles pelleted by high-speed centrifugation (HSC) are
exosomal-like in size (B88 nm diameter), and syntenin and
associated proteins (Syndecans, CD63, ALIX) are exclusively
present in the exosomal fraction as determined by density
gradient experiments16. Two different RNA-mediated inter-
ference (RNAi) molecules were used to efﬁciently knock down
ARF6, as compared with cells incubated in the presence of a
control (CNT) RNAi (Fig. 1a). ARF6 depletion did not have an
impact on cell growth or density and did not signiﬁcantly affect
the levels of syntenin, ALIX or syndecan-1 C-terminal fragment
(SDC1CTF) but nearly doubled the amount of CD63 in cells
(Fig. 1a,b). Exosomes were isolated from control and ARF6-
depleted cells by HSC and were analysed by western blot
(Fig. 1c,d). The two different RNAis targeting ARF6 induced a
signiﬁcant decrease in several exosomal proteins, such as syntenin
(down to 27 and 22% of the control levels), ALIX (27 and 46% of
the control levels), CD63 (54 and 60% of the control levels) and
SDC1CTF (30 and 22% of the control levels) (Fig. 1d), suggesting
that ARF6 expression is required for exosome production.
To complement these loss-of-function studies, we over-
expressed the wild-type form of ARF6 (ARF6-WT) and a fast-
cycling mutant (ARF6-T157N) (Fig. 2a). ARF6 overexpression
did not affect the expression of syntenin, ALIX or CD63 in the
cell lysates (Fig. 2a). Exosomes (HSC pellet) from control and
overexpressing cells were analysed by western blot (Fig. 2b). The
overexpression of the fast-cycling mutant ARF6-T157N signiﬁ-
cantly enhanced exosomal release of syntenin (195%), ALIX
(167%) and CD63 (131%), whereas overexpression of ARF6-WT
had no signiﬁcant effect (Fig. 2a,b). Finally, the effects of ARF6
silencing were partially prevented by overexpression of ARF6-
T157N (Supplementary Fig. 1a,b). Taken together, these data
reveal the importance of ARF6 and its GDP/GTP cycling for
syntenin exosomal production.
In an attempt to clarify whether speciﬁc ARF6 GEFs are
implicated in syntenin exosome production, the roles of ARNO,
GEP100 and EFA6, three GEFs expressed in MCF-7 cells were
investigated (Supplementary Fig. 2a). EFA6D is the most highly
expressed isoform of EFA6 in MCF-7 cells, consistent with
previous results showing the widespread tissue distribution of
EFA6D compared with the other isoforms27. Efﬁcient silencing of
ARNO, GEP100 and EFA6D expression (75, 85 and 93%
depletion, respectively, Supplementary Fig. 2b) decreased
syntenin exosome production (Supplementary Fig. 2c–e). Yet,
GEP100 and EFA6D silencing also decreased syntenin levels in
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the cell lysates making the interpretation of the results for these
two GEFs difﬁcult. In overexpression experiments, only ARNO
induced a signiﬁcant increase in syntenin exosomal secretion
(Supplementary Fig. 2f–h), suggesting that ARNO is involved in
exosome production.
We previously described that MCF-7 cells overexpressing
syntenin secrete more exosomes and exosomal markers such as
syntenin or CD63 (ref. 16). Interestingly, the depletion of ARF6
in cells largely prevents exosome stimulation induced by syntenin
overexpression (Fig. 2c,d). These results also indicate that ARF6
function is essential for syntenin exosome production.
ARF6 is implicated in ILV budding. As ARF6 is involved
in endocytosis22,23, we wondered whether ARF6 silencing
was precluding components from reaching the endosomal
compartment. We therefore investigated the internalization of
CD63, a syntenin PDZ ligand and a bona ﬁde exosomal marker,
by an antibody uptake from the plasma membrane. We observed
no increase in CD63 signal at the plasma membrane of ARF6-
depleted cells, and kinetic experiments revealed that ARF6
depletion did not signiﬁcantly affect CD63 internalization
(Fig. 3a and Supplementary Fig. 3a,b).
We then investigated the localization of CD63 in ARF6-
depleted cells by confocal microscopy, together with that of
various markers of the endocytic pathway. CD63 staining
presented a punctate distribution that partially colocalized with
the early endosomal marker EEA1 and the recycling marker
RAB11, in either control or ARF6-depleted cells. CD63 also
partially colocalized with the lysosomal marker LAMP2 (lysoso-
mal-associated membrane protein) in control cells, but this
colocalization was signiﬁcantly enhanced in ARF6-depleted cells
(Fig. 3b,c). These data suggest that ARF6 depletion did not block
the trafﬁcking of CD63 in early or recycling endosomes, but
blocks CD63 in late endosomal compartments.
The localization of endogenous ARF6 on late endosomes and
MVBs could not be investigated because of the lack of anti-ARF6
antibodies for microscopy experiments. As an approximation, we
looked at the localization of ﬂuorescently tagged ARF6. We used
the overexpression of RAB5(Q79L), which impairs endosomal
trafﬁcking, and induced the formation of enlarged endosomes
with a large number of ILVs inside28. Overexpressed ARF6
decorates the limiting membrane of RAB5(Q79L)-enlarged
endosomes (Supplementary Fig. 3c). This suggests a role for
ARF6 at the limiting membrane of MVBs. We also investigated
the role of the different GEFs in endosomal budding into
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Figure 1 | ARF6 depletion decreases syntenin exosome release. MCF-7 cells were treated with 2 different ARF6 RNAi (siARF6#1 and siARF6#2) or
non-targeting RNAi (siCNT). Total cell lysates (a) and the corresponding exosomes (c) were analysed by western blotting for different markers, as
indicated. Histograms represent mean signal intensities±s.d. in cell lysates or exosomes, relative to signals in siCNT cells or exosomes, calculated
for n independent experiments (b,d). SDC1CTF; syndecan-1 C-terminal fragment. *Po0.05, **Po0.01, ***Po0.001 (Student’s t-test).
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RAB5(Q79L)-enlarged endosomes. Proteins that normally
bud inside MVBs are expected to be found inside these
enlarged RAB5(Q79L) endosomes. Consistently, mCherry-
syntenin (mCh-syntenin) accumulates inside the lumen of
Cerulean-RAB5(Q79L) (Ce-RAB5(Q79L))-decorated enlarged
endosomes16. Confocal microscopy revealed that mCh-syntenin
ﬁlls the lumen of many Ce-RAB5(Q79L) endosomes in MCF-7
cells depleted for GEP100 or EFA6D (84% and 74% respectively
Supplementary Fig. 3d,e), suggesting that these ARF6 activators
are not involved in the ILV budding in the ARF6-syntenin-
exosomal pathway. In contrast, ARNO depletion drastically
reduced mCh-syntenin enrichment inside Ce-RAB5(Q79L)
endosomes, yielding only 50% mCh-syntenin ﬁlled endosomes
(Supplementary Fig. 3d,e). These results point again to a potential
role for ARNO in the ARF6 exosomal pathway.
To investigate the role of ARF6 in late endosomal trafﬁcking,
we performed electron microscopy experiments looking at the
trafﬁcking of CD63 to MVB. We monitored the localization of
anti-CD63:HRP conjugates using peroxidase cytochemistry after
30min internalization. The size of the stained vesicles was not
affected, but MVB morphology was clearly altered in ARF6-
depleted cells. In control cells, diaminobenzidine (DAB) staining
was found on limiting endosomal membranes and in close
association with ILVs, ﬁlling up the lumen of endosomes (Fig. 3d,
left images). In contrast, in ARF6-depleted cells, the staining was
associated with limiting membranes and with ILVs that were
peripherally located, the lumen of the endosomes remaining
largely empty (Fig. 3d,e). This was reminiscent of the MVB
morphology in syntenin RNAi-treated cells16 (Fig. 3d,e). These
electron microscopy experiments indicate that ARF6 has an
impact on ILV budding in endosomes to form MVB and support
a role for ARF6 in exosome biogenesis.
ARF6 controls EGFR degradation. Despite the large literature
on ARF6, to our knowledge, this small GTPase has never been
implicated in late endosomal sorting29. To clarify the functional
speciﬁcity of ARF6 in late endosomal trafﬁcking, we tested
whether ARF6 might also inﬂuence sorting and/or degradation of
MVB cargo destined for lysosomal degradation. Receptor protein
targeting for degradation through the MVB pathway classically
depends on ligand-stimulation, ubiquitination and ESCRTs10.
EGFR sorting to ILVs/MVBs before its lysosomal degradation
upon EGF stimulation is the paradigm of such ESCRT-dependent
pathway. Interestingly, in ARF6-depleted cells, the degradation of
EGFR induced by EGF stimulation was strongly reduced
compared with controls (Fig. 4a,b). Consistently, the cellular
level of EGFR was signiﬁcantly higher in ARF6-depleted cells
(Fig. 4c). EGFR was not released in exosomes (Supplementary
Fig. 4a), indicating that the increased amount of EGFR in the
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Figure 2 | ARF6 and ARF6 cycling are required for syntenin exosome release. MCF-7 cells were transiently transfected with an expression
vector for wild-type ARF6 (þARF6-WT), an expression vector for the fast cycling mutant of ARF6 (þARF6-T157N) or the empty vector (pCDNA3)
as control. (a) Total cell lysates and corresponding exosomes were collected 24 h after transfection and analysed by western blotting for different markers,
as indicated. (b) Histograms represent mean±s.d. signal intensities in exosomes, relative to signals in siCNT exosomes, calculated for n independent
experiments. (c) MCF-7 cells were treated with ARF6 RNAi (siARF6#2 and siARF6#1) or non-targeting RNAi (siCNT) for 48 h and then transiently
transfected with an expression vector for wild-type syntenin (þ Syntenin) or the empty vector (pCDNA3) as control. Total cell lysates (c) and
corresponding exosomes (d) were collected 24 h after transfection and analysed by western blotting for different markers, as indicated. (d) Histograms
represent mean signal intensities±s.d. in exosomes, relative to signals in siCNT exosomes, calculated for n independent experiments. siARF6#1 and
siARF6#2 data were pooled for quantiﬁcation and statistical analysis. *Po0.05, **Po0.01, ***Po0.001 (Student’s t-test).
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MCF-7 cell after ARF6 depletion is not due to a defect in
exosomal secretion. Plasma membrane levels of EGFR were not
reduced in ARF6-depleted cells, as shown by biotinylation
experiments (Fig. 4d and Supplementary Fig. 4b,c). The main
difference was a higher content of intracellular EGFR in ARF6-
depleted cells (Fig. 4d; Supplementary Fig. 4b,c). Finally,
ARF6-depleted cells were not less efﬁcient in internalizing
EGFR upon EGF stimulation (Fig. 4d; Supplementary Fig. 4b,c).
Taken together, these data indicate that ARF6 depletion impairs
the post-internalization degradation of EGFR and suggests that
ARF6 might also function in late endosomal trafﬁcking of EGFR
towards lysosomes.
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ARF6 is not involved in ESCRT-dependent HIV-1 budding.
Defects in ILV formation observed in ARF6-depleted cells might
be suggestive of defective ESCRT machinery. To test this possi-
bility, we investigated whether ARF6 depletion affects viral bud-
ding. Indeed, budding of retroviruses relies on ESCRTs to be
effective at the plasma membrane and/or in MVBs30. During
HIV-1 assembly, Gag molecules recruit components involved in
various steps of the ESCRT pathway (that is, TSG101, NEDD4L,
ALIX). This recruitment ultimately mediates a membrane ﬁssion
step required for virion release31. In the absence of those
components, Gag remains connected to the plasma membrane
and the budding does not occur32.
It was reported that ARF6 depletion does not affect cell
infection by HIV-1 vectors pseudotyped with the VSV-G
protein33. To determine whether ESCRT machinery involved in
viral budding was functionally affected or not by ARF6 depletion,
we infected MCF-7 cells, depleted or not for ARF6, with VSV-
pseudotyped replication competent HIV-1. ARF6 depletion was
veriﬁed to be and remain effective for the 6-day time course of the
experiment (Fig. 5a). To study viral budding, the production of
mature viral particles by infected MCF-7 cells was tested by
immunoﬂuorescence34. Non-permeabilized ﬁxed cells were
stained for cell surface Env. Cells were then permeabilized and
stained with anti-MAp17 (Fig. 5b). This antibody detects only the
cleaved matrix protein MAp17 and therefore labels mature virus
particles. MAp17 signals were found at the plasma membrane
and were barely detectable inside the cell, indicating that viral
budding mainly occurs at the plasma membrane. The
colocalization between Env and MAp17 conﬁrmed that the
viral material accumulated at cell periphery corresponds to
mature viruses present at the cell surface. We quantiﬁed the
amount of mature virus released from the cell surface by
measuring the total ﬂuorescence of MAp17 staining per cell
nucleus (Fig. 5c) and observed no signiﬁcant difference between
control and ARF6-depleted cells. Consistently, cellular viral
content (Fig. 5d) and viral release in the supernatant (Fig. 5e)
were also similar. These results indicate that ARF6 depletion does
not result in a general failure of ESCRT.
PLD2 is speciﬁcally implicated in ARF6 exosome biogenesis.
We then aimed to identify ARF6 effectors involved in ILV bud-
ding. We used the Ce-RAB5(Q79L) assay and efﬁcient silencing
(Supplementary Fig. 5a,b) as a rapid read-out of ILV formation
inside endosomes to monitor the impact of different ARF6
effectors, in particular the PIP5Ks and PLDs35,36.
Confocal microscopy revealed that mCh-syntenin ﬁlled the
lumen of Ce-RAB5(Q79L) endosomes in MCF-7 cells depleted
for PIP5Ks or PLD1 (86% for PIP5Ka, 94% for PIP5Kg and 93%
for PLD1; Fig. 6a,b and d), suggesting that these effectors are not
controlling ILV budding in the ARF6-syntenin-exosomal path-
way. In contrast, PLD2 depletion drastically reduced mCh-
syntenin enrichment inside Ce-RAB5(Q79L) endosomes, with
only 29% mCh-syntenin ﬁlled endosomes left (Fig. 6b,d).
Consistently, cells transiently co-transfected with Ce-
RAB5(Q79L) and HA-PLD2 show that PLD2 is found at the
limiting membrane of RAB5(Q79L) endosomes (Supplementary
Fig. 5c). Similar to ARF6, this suggests a role for PLD2 at the
limiting membrane of MVBs. The speciﬁc effect of PLD2 on
mCh-syntenin endosomal budding was conﬁrmed by using
isoform selective PLD inhibitors. Indeed, confocal microscopy
revealed that 85% of RAB5(Q79L) endosomes were ﬁlled with
mCh-syntenin in MCF-7 cells treated with a PLD1 inhibitor
(Fig. 6c,d), whereas this level was reduced to 49% in cells treated
with a PLD2 inhibitor (Fig. 6c,d). Moreover, we analysed the
exosomal release of cells treated with a PLD2 speciﬁc inhibitor by
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western blot (Fig. 6e,f). The amount of exosomal syntenin, ALIX
and CD63 was signiﬁcantly decreased (by 39%, 18%, and 44%,
respectively). Notably, more than one-third of the total PLD
activity was inhibited in ARF6-depleted cells (Supplementary
Fig. 5d), indicating that in MCF-7 cells PLD activity is
signiﬁcantly under the control of ARF6. PLD2 metabolizes
phosphatidylcholine (PC) into phosphatidic acid (PA) and
choline. Strikingly, the PA-binding domain of Spo-20 (PABD-
Spo20), a biosensor that speciﬁcally binds to PA37, decorates the
limiting membrane of Ce-RAB5(Q79L) endosomes, suggesting
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that PA synthesis may occur at this location (Supplementary
Fig. 6a). PLD2-depleted cells were analysed for their lipid content
by HPLC-MS/MS, and a signiﬁcant decrease in cellular PA was
found (Supplementary Fig. 6b). Low amounts of PA could also be
detected in exosomes; however, no signiﬁcant difference in
exosomal PA was detected upon PLD2 depletion (Supplementary
Fig. 6c). Interestingly, syntenin and in particular its PDZ1 domain
can directly interact with PA (Supplementary Fig. 6d). Altogether,
these data suggest that PLD2 is the effector of ARF6 involved in
ILV formation.
To evaluate the speciﬁc role of PLD2 in exosomal release, we
analysed the exosomes secreted by PLD1- and PLD2-depleted
cells (Fig. 7a,b). Two different RNAis targeting PLD2 decreased
the amount of syntenin, ALIX and CD63 in exosomes (by 52%,
63% and 77%, respectively). In contrast, no signiﬁcant difference
in the exosomal release of these markers was observed for PLD1
silencing. The ultrastructure of MVBs in PLD1- and PLD2-
depleted cells was further investigated by electron microscopy. As
observed in syntenin and ARF6-depleted cells, CD63-HRP
staining was found to be associated with limiting membranes
and on ILVs that were peripherally located, but the lumen of the
endosomes remained largely empty (Fig. 7c,d). Of note, PLD1-
depleted cells presented no signiﬁcant defect in CD63-HRP
staining compared with CNT cells (Fig. 7c, middle panel),
indicating that the ILVs are correctly formed in these cells. Taken
together, these results show that PLD2 is speciﬁcally required for
ILV formation and syntenin exosome biogenesis.
Discussion
In this study, we identify ARF6 as a regulator of the production of
syntenin exosomes. We show that ARF6 inhibition in cells leads to a
signiﬁcant decrease in exosomal proteins. Moreover, the fast cycling
mutant ARF6-T157N increases and rescues syntenin exosomal
secretion, indicating that the GDP/GTP complete cycle of ARF6 is
crucial for stimulating exosome production. Among the ARF6
GEFs, we obtained evidence that ARNO might be more directly
implicated in the control of ARF6-dependent exosomal secretion.
ARF6 has been implicated in the endocytosis of several
membrane proteins29,38. Here we show that ARF6 depletion does
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ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4477
8 NATURE COMMUNICATIONS | 5:3477 | DOI: 10.1038/ncomms4477 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
not inﬂuence the internalization rate of the syntenin cargo CD63.
Rather, CD63 accumulates in intracellular compartments. CD63
does not accumulate in early endosomes, which indicates that the
effect of ARF6 on exosome production cannot be explained by a
defect in early endocytosis. CD63 does not accumulate in
recycling endosomes either. Electron microscopy provided no
evidence for impaired fusion of MVB with the plasma membrane
as we did not observe CD63-MVB accumulation near the plasma
membrane. This differentiates ARF6 from the small GTPases
RAB27 and RAB35, which were previously shown to control
exosome secretion at this step39,40. In ARF6-depleted cells, CD63
concentrates at the level of LAMP2 late endosomes. Electron
microscopy experiments allowed to show that ARF6 is necessary
for CD63 intraluminal budding into MVBs. Loss of ARF6 does
not affect the size, but the ﬁlling of the endosome stained with
CD63. A difﬁculty for cells to produce and secrete exosomal
CD63 upon ARF6 downregulation would explain CD63
accumulation in the cells and in particular in late endosomal
compartments presenting a defect in ILV formation. Taken
together, the data indicate that ARF6 is not implicated in the
delivery of cargo to late endosomes but in the formation of ILVs.
Intriguingly, ARF6 depletion does not seem to block all ESCRT-
dependent processes as HIV budding is not affected. Yet, we
cannot exclude that ARF6-dependent intraluminal budding is
ESCRT-dependent, as the syntenin exosomal pathway depends
on ALIX and some ESCRT components16.
In this context, it has been shown that EGF treatment
speciﬁcally upregulates ESCRT-dependent ILV formation41.
Here we show that ARF6 controls EGFR late endosomal sorting
as its depletion results in increased cellular EGFR and in a lack of
EGFR degradation upon EGF stimulation. In ARF6-depleted
cells, EGFR accumulates inside the cell. Recycling defects can
apparently be excluded as ARF6 depletion does not reduce
plasma membrane EGFR. Thus, ARF6 also seems to have an
impact on the formation of degradative late endosomes (destined
for fusion with lysosomes, with ILV degradation) and by
extension on related ESCRTs. Interestingly, it has recently been
shown that the ARF6 effector PIP5K (speciﬁcally the gamma i5
isoform) is required for the EGFR sorting into ILVs of the MVB
upon EGF stimulation in MDA-MB-231 cells42. This was
dependent on the ESCRT component Hrs. Yet it was not
investigated whether this was dependent on ARF6 and whether
this PIP5K might affect exosomal release. Depletion of PIP5K
gamma did not have an impact on syntenin endosomal budding,
but levels of this enzyme are low in MCF-7 cells.
Indeed, looking for ARF6 effectors that might support syntenin
exosomal production, we tested the various PIP5Ks and PLDs
isoforms expressed in MCF-7 cells for their effect on endosomal
budding. We found no evidence for a role of any of the PIP5Ks in
syntenin endosomal budding. This is somehow consistent with a
general role for ARF6-PIP5K in endosomal recycling from the
perinuclear compartment to cell surface43 and in particular with a
role for ARF6-PIP5K in the plasma membrane recycling of the
syntenin-PDZ cargo syndecan in a syntenin-phosphatidylinositol
4,5-phosphate (PI(4,5)P2)-dependent manner26.
Two isoforms of mammalian PLD, PLD1 and PLD2 have been
identiﬁed44. Although PLD1 was previously shown to be localized
to late endosomes and lysosomes45, our observations exclude a
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role for PLD1 in the ARF6-syntenin exosomal pathway. On the
contrary, we established a clear role for PLD2 in ILV budding and
syntenin exosomes. In some circumstances, ARF6 has been
shown to selectively stimulate PLD2 activity46, but to our
knowledge no role for PLD2 in late endosomal trafﬁcking has
been documented; nevertheless, PLD2 was reported to be
enriched and speciﬁcally sorted on exosomes when over-
expressed in RBL-2H3 cells47. Interestingly, ARF6 has been
implicated in the shedding of microvesicles from the plasma
membrane, and the data also suggest a role for PLD in this
process48. Yet, this was done with different methodological
approaches and in different cells. It might thus be that, depending
on the signalling context, ARF6-PLD exerts the same topological
effects (budding from the cytosol) at different subcellular
locations, such as the plasma membrane or the endosomal
membrane.
PLDs are known to metabolize phosphatidylcholine into
phosphatidic acid (PA). With a very small negatively charged
headgroup close to the acyl chains, PA generated in the inner
leaﬂet of membranes is likely to induce a negative membrane
curvature49, which might favour endosomal intraluminal
budding. In the same manner, the cone-shaped structure of
ceramide may induce spontaneous negative curvature in the
membrane bilayer promoting membrane invagination14. Local
lipid compositions that might reorganize into specialized
endosomal regions might induce membrane bending and
induce ILV formation. Indeed, it has been shown that lipids
and a pH gradient are sufﬁcient to form ILVs in LBPA-containing
liposomes50. We found that a PA probe enriches at the limiting
membrane of RAB5(Q79L) endosomes that can undergo
endosomal budding and create giant ‘MVB-like’ organelles28.
Moreover, syntenin can directly interact with PA, which might
support syntenin-ALIX complexes to be sorted in PA-enriched
lipid microdomains. It is thus tempting to speculate that the
product of PLD2 activity, PA, is directly involved in ILV budding.
PLD2-depleted cells were analysed by HPLC-MS/MS for their
lipid content and present a signiﬁcant decrease in total cellular
PA level. We also found that exosomes contain low levels of PA
that were not affected by PLD2 silencing. This might be because
the PLD2-generated PA required for exosome production might
be restricted to nascent budding ILVs, consistent with the
localization of the PA probe at the limiting membrane but not
inside RAB5(Q79L) endosomes. It is also worth to mention that
PA can be produced through various biosynthetic pathways that
include PLD1/2, up to 10 diacylglycerol kinases and various
lysophosphatidic acid acyl-transferases. Therefore, the exact
source of the PA detected on exosomes remains to be directly
established.
Altogether an appealing model would be that ARF6-PLD2-PA
controls syntenin-ALIX ILV formation and thereby subsequent
exosomal release, with effects on ESCRTs that are selective or
depend on context (that is, speciﬁc cargo).
Methods
Expression vectors and reagents. For gain-of-function studies in cells, the cDNA
encoding full-length non-tagged syntenin was cloned in pcDNA3.1/Zeo(þ )
(Invitrogen). The cDNA encoding mCherry-syntenin was derived from the eGFP-
syntenin cDNA construct19, by restriction ligation. The expression vector for
Ce-RAB5(Q79L) was received from W. Annaert (K.U. Leuven, Belgium) and
non-tagged ARF6-WT and ARF6-T157N constructs were generated from
mCherry-tagged forms provided by M. Franco (IPMC, Sophia Antipolis). For the
rescue experiments, we used open-reading frames where we generated three point
mutations in the target sequence of the siRNA. All constructs were veriﬁed by
sequencing.
All RNAi targeting human sequences (siGENOME and On-target plus) and the
non-targeting control RNAi (siCNT) were purchased from Dharmacon Inc.
ARF6#2 (50-GGUCUCAUCUUCGUAGUGG-30); ARF6#1 (50-GCACCGCAUU
AUCAAUGACCG-30); PIP5K a RNAi (ON-TARGET plus Smart pool L-004780),
syntenin (50-GCAAGACCUUCCAGUAUAA-30), PLD1 siGENOME SMARTpool
(M-009413), PLD1#2 (50-GAAGAACAAUUCCUUGGUA-30), PLD1#1 (50-GAAG
AUUACUUGACAAAGA-30), PLD2 siGENOME SMARTpool (M-005064),
PLD2#2 (50-GGACCGGCCUUUCGAAGAU-30); PLD2#1 (50-CAGCAUGGCGG
GACUAUAU-30). PIP5K g RNAis (PAN targeting speciﬁcally isoform 1 and 2 and
RNAis targeting isoform 5) were kindly provided by R. Anderson (Madison, USA).
qPCR primer sequences are supplied in Supplementary Table 1.
Anti-syntenin, anti-syndecan-1CTF and anti-ALIX antibodies were as described
earlier16. Other antibodies were from commercial sources and were used as
recommended by the manufacturers. Antibodies directed against CD63 (MEM-
259) was from Abcam (dilution 1/500), Tubulin (T6199) from Sigma-Aldrich
(dilution 1/10,000), EEA1 (610456) from BD Biosciences (dilution 1/250), LAMP2
(PA1-655) from Thermo Scientiﬁc (dilution 1/2,000), EGFR from Cell Signaling
(2,232, dilution 1/1,000), SUgp120 from NIH AIDS Research (clone 2G12, used at
0,5 mgml 1), HIV-1SF2 p24 Antiserum from NIH AIDS Research (catalogue
number 4250, dilution 1/500), MAp17 from Hybridolab (clone 18A, dilution
1/500) and ARF6 was from Santa Cruz (sc-7971, dilution 1/500). The CAY10593
inhibitor (used at 10 mM) was purchased from Cayman Chemical (13206) and the
CAY10594 inhibitor (used at 10 mM) from Santa Cruz (sc-223874).
Statistical analysis was performed using the standard two-tailed Student t-test,
and *Po0.05, **Po0.01, ***Po0.001 were considered statistically signiﬁcant.
Cells and transfections. MCF-7 cells were obtained from ATCC (Manassas, VA).
Cells were routinely grown in DMEM/F12 (1:1) medium (Life technologies, Gai-
thersburg, MD) supplemented with 10% fetal calf serum (FCS) (Hyclone, Logan,
UT). Serum used for experiments was depleted of exosomes, by prior overnight
centrifugation at 140,000 g. For transient expressions, the cells were transfected
the day after plating using Fugene HD reagent (Roche). For RNAi experiments,
cells at a conﬂuence of 50% were transfected with 20 nM RNAi using Lipofecta-
mine RNAiMAX reagent (Life technologies, USA); cells were analysed 48 or 72 h
after RNAi treatment. For drug treatment, cells were simultaneously treated with
the PLD1 inhibitor CAY10593 or the PLD2 inhibitor CAY10594 and transiently
transfected to coexpress mCh-syntenin with Ce-RAB5(Q79L), for 24 h.
Exosomes and total cell lysates. For comparative analyses, in gain- and loss-of-
function studies, exosomes were collected from equivalent amounts of culture
medium, conditioned by equivalent amounts of cells. After the required time of
cDNA or RNAi treatments, the cell layers were washed twice with PBS and
refreshed with DMEM/F12 containing 10% exosome-depleted FCS. Cell-condi-
tioned media were collected 16 h later. Exosomes were isolated from these media by
three sequential centrifugation steps at 4 C: 10min at 500 g, to remove cells;
30min at 10,000 g, to remove cell debris; and 3 h at 140,000 g, to pellet exo-
somes, followed by one wash (suspension in PBS/centrifugation at 140,000 g),
to remove soluble serum and secreted proteins. Exosomal pellets prepared by
differential HSC exosomes were then re-suspended in lysis buffer (PBS supple-
mented with 1% NP40, 10mM EDTA and protease inhibitor cocktail containing
1 mgml 1 antipain, 1 mgml 1 pepstatin, 15mgml 1 benzamidine and 1mgml 1
leupeptin). The corresponding cell layers were washed in cold PBS and scraped on
ice. Lysates from corresponding cultures were cleared by centrifugation at 300 g
for 5min at 4 C and then re-suspended in lysis buffer. Although little variations
were observed from sample to sample (max 10%), exosomal amount loaded for the
western blot was normalized according to the number of parent cells from where
exosomes were secreted.
EGFR internalization. MCF-7 cells were transfected with either siCNT or
siARF6#2. After 48 h of transfection, cells were washed three times with PBSþ
MgCl2 and biotinylated for 20min with reducible sulfo-NHS-SS-biotin (Pierce) at
4 C. After stimulation with EGF 100 ngml 1, cell surface biotin was removed by
treatment (2 20min) at 4 C with sodium 2-mercaptoethanesulphonate (MesNa,
Sigma). To determine the intracellular pools of biotinylated receptors, cells were
lysed and incubated with avidin resin (Thermo Scientiﬁc). After capture and
washes, the complexes were separated by SDS–PAGE and EGFR was detected by
western blot. Signals were detected by chemiluminescence and quantiﬁed using
ImageJ (National Institutes of Health, Bethesda, MD, USA).
Western blotting. The proteins were heat-denaturated in Laemmli sample buffer
and fractionated in 12.5% gels by SDS–PAGE, electro-transferred to nitrocellulose
membrane, stained with Ponceau red and immunoblotted with the indicated
antibodies. Signals were visualized with enhanced chemiluminescence detection
reagent (Amersham Pharmacia Biotech) and were quantiﬁed by densitometric
scanning, using ImageJ. Full scans of all western blots are supplied in
Supplementary Fig. 7.
CD63 internalization. MCF-7 cells were treated with siCNT or siARF6 and plated
in 24-well dishes at a concentration of 100,000 cells per well. After 72 h, the cells
were incubated for 30min at 4 C with 2 mgml 1 anti-CD63 antibody in complete
media, washed twice in PBS and then incubated at 37 C. At each time point, cells
were washed with PBS and ﬁxed with 4% paraformaldehyde (PFA), 15min at RT
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and incubated 30min in PBS containing 3% BSA and 0.05% saponin with Alexa-
488 donkey anti-mouse IgG and Hoechst. The anti-CD63 internalized was esti-
mated by confocal microscopy, using one focal plane. The percentage of internal
CD63 was measured by ImageJ.
Immunoﬂuorescence staining and confocal microscopy. Cultured cells on glass
coverslips were ﬁxed with 4% PFA for 15min, washed in PBS and then incubated
with the indicated antibodies with PBS containing 3% BSA and 0.05% saponin.
Coverslips were mounted on DABCO/Mowiol and observed with a Zeiss Meta
confocal microscope (LSM 510 META, Zeiss, France) with a UV laser and  63
objectives. Confocal images were analysed using ImageJ and Photoshop (Adobe,
San Jose, CA) software.
Electron microscopy. For the MVB morphology studies, cells were incubated for
30min at 37 C with an anti-CD63 antibody (Abcam) labelled with horseradish
peroxidase (Z 25054 Molecular Probes). The cells were then washed with PBS and
ﬁxed for 1 h in 3% glutaraldehyde in 0.1M sodium cacodylate (NaCaC) buffer.
After several washes in 0.1M NaCaC, the cells were incubated with diamino-
benzidine (DAB; Sigma) in 0.05M Tris-HCl, pH 7.6. The enzymatic reaction was
initiated by adding H2O2 at a ﬁnal concentration of 0.01% and allowed to proceed
for 30min. After washing in Tris-HCl buffer, the cells were post-ﬁxed for 1 h with
1% osmium tetroxide in 0.1M phosphate buffer, washed, scraped, re-suspended in
2% agar and pelleted. Sliced agar blocks were dehydrated in a series of ethanol and
embedded in Agar 100 resin polymerized for 48 h at 60 C. sixty nanometre sec-
tions (Ultracut E Leica) were counterstained with 2% uranyl acetate and lead citrate
(Reynold’s), and were examined with a ZEISS EM 912 and images were taken with
a gatan Bioscan camera. MVBs sectional areas were measured using ImageJ soft-
ware, and the data were analysed using Excel software.
HIV-1 assays. Wild-type replication competent viruses (HIV NL4.3 WT), pseu-
dotyped with vesicular stomatitis virus envelope glycoprotein (VSV-G) were pro-
duced in HEK293T cells by transient transfection with a 5:1 plasmid ratio, using
the calcium-phosphate precipitation technique. Three days after transfection,
viruses were collected, frozen and kept for further application. Virus concentration
was determined by CAp24 quantiﬁcation in the supernatant, using a HIV-1 p24
ELISA kit (PerkinElmer Life Science, Inc.). MCF-7 cells were transfected with
either siCNT, siARF6#1 or siARF6#2 as described above and grown in 24-well
plates, on coverslips. After 3 days, 2 105 MCF-7 cells were infected with 50 ng of
Cap24-pseudotyped virus. Cells were washed four times, 4 h after infection. Three
days after infection, infected cells on coverslips were washed and ﬁxed with 4%
PFA in PBS for 20min. For extracellular staining of Env, cells were incubated for
1 h at RT with anti-Env HIV-1 gp120 IgG1k mouse monoclonal antibody (clone
2G12, NIH AIDS Research and Reference Reagent Programme, Division of AIDS,
NIAID). Mature viral particles were stained using an anti-MAp17 IgG2a mouse
monoclonal antibody (clone 18A, Hybridolab) in PBS containing 1% BSA and 0.1%
triton-X100. Cells were then washed and labelled with a FITC-conjugated goat
anti-mouse-IgG1 antibody (SouthernBiotech) and Cy3-conjugated goat anti-
mouse-IgG2a (Jackson Immunoresearch), followed by Alexa488-conjugated goat
anti-FITC (Molecular Probes). After wash in PBS, coverslips were mounted in
ProLong Gold antifade reagent with DAPI (Life Technologies). Confocal images
were obtained using a LSM 700 confocal microscope (Carl Zeiss) over a  63
objective. Z-stack optical sections were acquired at 0.2 mm depth increments for
imaging or 1 mm increments for quantiﬁcation. For quantiﬁcation, cells were
randomly chosen and about 10 contiguous optical sections contained the whole-
cell ﬂuorescence information. Both green and red laser excitation were intercalated
to minimize cross-talk between the acquired ﬂuorescence channels. Analysis of
viral budding was performed using ImageJ. Viral release per cell was determined by
CAp24 quantiﬁcation in the supernatant, using a HIV-1 p24 ELISA kit (Perki-
nElmer Life Science, Inc.) divided by the number of cells.
Lipid overlay assays. GST and GST-tagged Syntenin-PDZ1 domain were pro-
duced in E. Coli (ER2566) and puriﬁed with glutathione beads. Overlay assays were
performed as described in ref. 51. 100 pmol lipids were immobilized on the
nitrocellulose membrane. The fat-free milk blocked membranes were incubated
with 5 mgml 1 GST-tagged proteins. Bound proteins were detected using the
primary anti GST antibody, HRP-conjugated secondary antibody and ECL
detection.
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